deSouza Ruth Mary, Schapira Anthony
a Department of Clinical Neurosciences , Institute of Neurology, University College London , London , UK.
Expert Opin Pharmacother. 2017 Jun;18(9):937-943. doi: 10.1080/14656566.2017.1329819. Epub 2017 May 23.
The major unmet needs in the medical treatment of Parkinson disease (PD) are reduction of motor side effects from dopaminergic drugs, management of non-motor symptoms and disease modification. Areas covered: Motor fluctuations and OFF periods are a significant determinant of quality of life in PD and reducing their duration and severity can significantly improve motor function. This aim may be partly facilitated by the development of effective adjunctive drugs for dopamine replacement. Safinamide (Xadago), which is a first generation anticonvulsant, has pharmacological properties which are of interest in the context of neurodegenerative diseases, leading to research into its potential as an adjunct to levodopa in PD. Expert opinion: Although its mechanism has not been fully defined, safinamide provides enhanced symptom control of motor function in advanced PD and improves quality of life.
帕金森病（PD）医学治疗中尚未满足的主要需求包括减少多巴胺能药物的运动副作用、管理非运动症状以及疾病修饰。涵盖领域：运动波动和“关”期是PD患者生活质量的重要决定因素，缩短其持续时间和减轻其严重程度可显著改善运动功能。多巴胺替代有效辅助药物的研发可能部分有助于实现这一目标。第一代抗惊厥药沙芬酰胺（Xadago）具有在神经退行性疾病背景下令人感兴趣的药理特性，从而引发了对其作为PD中左旋多巴辅助药物潜力的研究。专家观点：尽管其作用机制尚未完全明确，但沙芬酰胺可增强晚期PD患者运动功能的症状控制并改善生活质量。
